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Background
A prophylactic vaccine represents the ultimate strategy for
blocking the HIV transmission in the general population.
To this challenging unprecedented scientific goal, in the
last years we have developed a human immunodeficiency
virus type 1 (HIV-1) vaccine model based on HIV-1
Pr55gag virus-like particles (HIV-VLPs), produced in a
baculovirus expression system and presenting a gp120
molecule from a Ugandan HIV-1 isolate of clade A (HIV-
VLPAs). The HIV-VLPAs show the induction in BALB/c
mice of systemic and mucosal neutralizing antibodies as
well as cytotoxic T lymphocytes, by intraperitoneal as well
as intranasal administration.
Methods
In the present study, the generation of novel chimeric HIV
gp120 and gp140 envelope glycoproteins, presenting het-
erologous signal sequences and/or trans-membrane
regions, has been planned to improve the density and the
trimeric conformation of the molecules presented on the
surface of the HIV-VLPs. Moreover, aminoacid substitu-
tions in the gp140 glycoprotein sequence have been
designed in order to stabilize gp120-gp41 association as
well as gp41-gp41 interaction.
Results
HIV-1 gp120 or gp140 chimeric genes, based on the
Ugandan HIV-1 isolate of clade A, have been generated
and transposed into baculovirus-based bacmids for
expression in insect cells. Analyses of the VLPs expressing
such novel chimeric HIV envelope glycoproteins are cur-
rently ongoing.
Conclusion
The development of novel HIV envelope glycoproteins
presented as stable trimeric complex on the surface of
VLPs and possibly exposing broadly conserved epitopes
should allow the efficient induction of systemic as well as
mucosal humoral response with a broad neutralization
activity on different HIV field isolates.
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